U.S., Jan. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07311538) titled 'Phase IIa Study of BRY812 Monotherapy in Advanced Gynecological Malignancies' on Nov. 18, 2025.
Brief Summary: This study is a single-arm, open-label, multicenter Phase IIa trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of BRY812 for Injection in patients with LIV-1-positive advanced gynecological malignancies. The study comprises two cohorts. For Cohort 1 (ovarian cancer), a Simon's two-stage design is adopted. In the first stage, 13 evaluable subjects will be enrolled. If fewer than 3 subjects achieve an objective response among these 13, enrollment in this cohort will be terminated. Otherwise, the coh...